In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 200 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]	Technology appraisal guidance	TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]	Technology appraisal guidance	TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]	Technology appraisal guidance	TBC
In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death	Interventional procedures guidance	19 November 2026
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance	TBC
Indoor air quality at home	Quality standard	TBC
Infection prevention and control update	Quality standard	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	21 May 2026
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance	TBC
Insulin efsitora alfa for treating type 2 diabetes [ID6499]	Technology appraisal guidance	22 October 2026
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]	Technology appraisal guidance	26 August 2026
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]	Technology appraisal guidance	TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]	Technology appraisal guidance	TBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]	Technology appraisal guidance	21 May 2026
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]	Technology appraisal guidance	TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance	TBC
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]	Technology appraisal guidance	10 July 2026
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]	Technology appraisal guidance	TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]	Technology appraisal guidance	3 September 2026
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]	Technology appraisal guidance	2 December 2026
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance	TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Technology appraisal guidance	TBC
Managing common infections - antimicrobial prescribing guidelines	NICE guideline	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]	Technology appraisal guidance	TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]	Technology appraisal guidance	TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]	Technology appraisal guidance	TBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]	Technology appraisal guidance	28 September 2016
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance	15 October 2026
Mental health guidelines	NICE guideline	TBC

Results per page

10
25
50
All